Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss.
BACKGROUND
Hyperparathyroidism in humans and continuous parathyroid hormone (cPTH) treatment in mice cause bone loss by regulating the production of RANKL and OPG by stromal cells (SCs) and osteoblasts (OBs). Recently, it has been reported that T cells are required for cPTH to induce bone loss as the binding of the T cell costimulatory molecule CD40L to SC receptor CD40 augments SC sensitivity to cPTH. However it is unknown whether direct PTH stimulation of T cells is required for cPTH to induce bone loss, and whether T cells contribute to the bone catabolic activity of PTH with mechanisms other than induction of CD40 signaling in SCs.


RESULTS
Here we show that silencing of PTH receptor 1 (PPR) in T cells blocks the bone loss and the osteoclastic expansion induced by cPTH, thus demonstrating that PPR signaling in T cells is central for PTH-induced reduction of bone mass. Mechanistic studies revealed that PTH activation of the T cell PPR stimulates T cell production of the osteoclastogenic cytokine tumor necrosis factor alpha (TNF). Attesting to the relevance of this effect, disruption of T cell TNF production prevents PTH-induced bone loss. We also show that a novel mechanism by which TNF mediates PTH induced osteoclast formation is upregulation of CD40 expression in SCs, which increases their RANKL/OPG production ratio.


CONCLUSIONS
These findings demonstrate that PPR signaling in T cells plays an essential role in PTH induced bone loss by promoting T cell production of TNF. A previously unknown effect of TNF is to increase SC expression of CD40, which in turn increases SC osteoclastogenic activity by upregulating their RANKL/OPG production ratio. PPR-dependent stimulation of TNF production by T cells and the resulting TNF regulation of CD40 signaling in SCs are potential new therapeutic targets for the bone loss of hyperparathyroidism.
Tawfeek
Hesham
H
Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, Atlanta, Georgia, United States of America.
Bedi
Brahmchetna
B
Li
Jau-Yi
JY
Adams
Jonathan
J
Kobayashi
Tatsuya
T
Weitzmann
M Neale
MN
Kronenberg
Henry M
HM
Pacifici
Roberto
R
D000818:Animals; D001862:Bone Resorption / Q000139:chemically induced* / Q000378:metabolism* / Q000473:pathology; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D020868:Gene Silencing; D006801:Humans; D008297:Male; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D053244:Osteoprotegerin / Q000096:biosynthesis; D010281:Parathyroid Hormone / Q000494:pharmacology*; D053245:RANK Ligand / Q000096:biosynthesis; D044168:Receptor, Parathyroid Hormone, Type 1 / Q000172:deficiency* / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D053244:Osteoprotegerin; D010281:Parathyroid Hormone; D053245:RANK Ligand; D044168:Receptor, Parathyroid Hormone, Type 1; D014409:Tumor Necrosis Factor-alpha
J Bone Miner Res. 2000 Oct;15(10):1912-23
11028443
Clin Endocrinol (Oxf). 1996 Jun;44(6):697-702
8759182
N Engl J Med. 1986 Jun 26;314(26):1676-86
3520321
J Clin Endocrinol Metab. 1996 Oct;81(10):3450-4
8855783
J Bone Miner Res. 1987 Dec;2(6):595-610
3455637
J Clin Invest. 2001 Feb;107(3):277-86
11160151
J Clin Invest. 2000 Nov;106(10):1229-37
11086024
Bone. 2010 Sep;47(3):461-71
20452473
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13960-5
11717453
Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3324-9
15728361
J Bone Miner Res. 2004 Jul;19(7):1165-71
15177000
Endocrinology. 2002 Aug;143(8):3036-43
12130570
J Immunol. 2005 Dec 15;175(12):8287-95
16339569
N Engl J Med. 2007 Aug 30;357(9):905-16
17761594
J Biol Chem. 2000 Sep 1;275(35):27274-83
10854439
J Bone Miner Res. 1996 Oct;11(10):1474-81
8889847
Nat Neurosci. 1999 Nov;2(11):941-3
10526330
Endocrinology. 2003 May;144(5):1761-9
12697681
Cell Metab. 2008 Aug;8(2):132-45
18680714
Nephron. 1993;64(4):592-9
8396211
Cell Metab. 2009 Sep;10(3):229-40
19723499
PLoS One. 2008 Aug 13;3(8):e2942
18698360
J Endocrinol Invest. 2000 May;23(5):273-9
10882144
Development. 2002 Jun;129(12):2977-86
12050144
Endocrinology. 2001 Dec;142(12):5050-5
11713196
J Clin Invest. 2006 May;116(5):1186-94
16670759
Nat Med. 2007 Jul;13(7):791-801
17618270
Endocrinology. 2001 Sep;142(9):4047-54
11517184
J Bone Miner Res. 1989 Jun;4(3):283-91
2763869
J Biol Chem. 1996 Nov 15;271(46):28890-7
8910536
Endocrinology. 2005 Nov;146(11):4577-83
16081646
J Bone Miner Res. 1992 Jan;7(1):65-72
1532281
Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):15087-92
17848519
J Biol Chem. 2009 May 8;284(19):12654-62
19279010
Endocrinology. 2005 Apr;146(4):1863-70
15625242
J Clin Endocrinol Metab. 1999 May;84(5):1562-6
10323380
J Bone Miner Res. 2002 Jan;17(1):77-90
11771672
J Clin Invest. 1999 Aug;104(4):399-407
10449432
J Endocrinol. 2005 Sep;186(3):549-57
16135674
J Clin Invest. 2000 Dec;106(12):1481-8
11120755
Pediatr Res. 1995 Apr;37(4 Pt 1):507-11
7596693
J Bone Miner Res. 1999 Dec;14(12):2159-66
10620076
Leuk Lymphoma. 1997 May;25(5-6):415-25
9250811
Immunity. 2001 Nov;15(5):763-74
11728338
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10405-10
12923292
Trends Endocrinol Metab. 2004 Mar;15(2):60-5
15036251
Endocrinology. 1992 Jan;130(1):300-6
1309334